Neurodegenerative Disease
Prion Disease
How a single misfolded protein turns healthy ones into copies of itself
A prion is a protein folded into a self-templating shape. One misfolded molecule converts the next; the chain reaction destroys neurons and is heat-, chemical-, and irradiation-resistant. No DNA. No RNA. Just bad geometry.
- ProteinPrP (encoded by PRNP on chr 20)
- ConformersPrP^C (α-helix) → PrP^Sc (β-sheet)
- sCJD incidence~1 in a million per year
- Incubation5–30 years, sometimes longer
- Survival after symptoms~5 months (sCJD)
- Decontamination134 °C × 18 min + 1N NaOH
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
How a prion replicates
Every mammal makes a protein called PrP — the prion protein — encoded by the PRNP gene. Its normal form, PrPC, is a glycoprotein anchored to the outside of neurons by a GPI tail. Its physiological role is still debated; mice with PrP knocked out are largely normal but show subtle peripheral nerve and myelin maintenance defects, and probably abnormal copper handling. The protein matters; we just don't fully understand why.
The disease form, PrPSc ("Sc" for scrapie, the historical sheep prion disease), has exactly the same amino acid sequence as PrPC. The difference is conformational: where PrPC is rich in alpha-helices, PrPSc is rich in beta-sheets. The beta-sheet form is insoluble, protease-resistant, and stacks readily into amyloid fibrils.
The mechanism of replication is template-directed misfolding. When PrPSc physically contacts PrPC, the contact forces the normal protein to refold into the same beta-sheet shape. Now there are two infectious molecules. Each can convert two more. Fibrils fragment, creating new seeds. The dynamics look like nucleated polymerization, and the kinetics fit autocatalysis.
Aggregates accumulate in the brain over years, killing neurons by mechanisms that include direct mitochondrial damage, synaptic loss, and astrocyte/microglial activation. The macroscopic tissue takes on a sponge-like pattern of vacuolation — hence spongiform encephalopathy.
The human prion diseases
- Sporadic CJD (sCJD). Roughly 1 case per million people per year worldwide. No identifiable trigger; presumed to arise from rare spontaneous misfolding of PrP. Peak incidence in the 60s. Median survival from symptom onset is about 5 months.
- Familial / genetic prion disease. About 15% of cases. PRNP mutations push the protein toward misfolding. Examples: E200K (familial CJD, common in some Sephardic Jewish populations), D178N + 129V (fatal familial insomnia, with insomnia, dysautonomia, dementia), D178N + 129M (familial CJD), P102L (Gerstmann-Sträussler-Scheinker).
- Iatrogenic CJD (iCJD). Transmitted by medical procedures: contaminated cadaveric human growth hormone (>200 cases globally, 1959–1985), dura mater grafts (>200 cases), corneal transplants, and reused neurosurgical instruments. Modern recombinant hGH eliminated this risk.
- Variant CJD (vCJD). Caused by eating BSE-contaminated beef in the UK, late 1980s–1990s. About 178 UK cases confirmed; small numbers in France, Ireland, Italy, the US, Saudi Arabia. Younger patients than sCJD (median 27 years), longer course (~14 months), distinctive florid plaques on neuropathology.
- Kuru. Ritual mortuary cannibalism among the Fore people of Papua New Guinea spread kuru — peak ~200 deaths/year in the 1950s. Once the practice ended, incidence collapsed. The longest documented incubation was over 50 years.
Why prions are nearly indestructible
Standard hospital sterilization is helpless against prions. The beta-sheet amyloid is stable to:
- Standard autoclaving (121 °C, 15 min).
- Ethanol, 10% formaldehyde, glutaraldehyde — they actually fix the prion, making it harder to remove.
- Boiling, dry heat, UV, ionizing radiation, ultrasound at routine doses.
- Standard nucleases and proteases at routine conditions.
Effective decontamination protocols use 134 °C autoclaving for 18 minutes plus 1N NaOH or 2N sodium hypochlorite. WHO and CDC guidelines treat suspect surgical instruments as one-time use, or destroy them by incineration. This is why neurosurgical centers screen carefully for CJD before procedures and segregate or destroy instruments after high-risk cases.
Diagnosing prion disease
Rapidly progressive dementia in a middle-aged or older patient should raise suspicion. The clinical picture combines cognitive decline, myoclonus (sudden involuntary jerks, often startled by noise), ataxia, visual disturbance, and akinetic mutism late in the course. The exam often outpaces the imaging.
- EEG. Periodic sharp wave complexes (1–2 Hz) — about two-thirds sensitive for sCJD, less for other types.
- MRI. Diffusion-weighted imaging shows cortical ribbon hyperintensity and bright basal ganglia (pulvinar sign in vCJD).
- CSF. 14-3-3 protein, total tau, and neuron-specific enolase elevated. The newer RT-QuIC assay detects PrPSc seeding activity directly with >90% sensitivity and >98% specificity; it has replaced 14-3-3 as the leading biomarker.
- Brain biopsy. Rarely done — risk of iatrogenic transmission via instruments. Post-mortem neuropathology remains the gold standard: spongiform vacuolation, neuronal loss, gliosis, and PrP plaques on immunohistochemistry.
A heretical idea
For most of the 20th century, the diseases that became "prion diseases" were called slow viruses — though no one could find a virus. In 1982, Stanley Prusiner, a neurologist at UCSF, published in Science that the infectious agent in scrapie was a protein alone — and proposed the term prion. The hypothesis violated the central dogma of molecular biology and was met with intense skepticism. Bumper stickers in Bethesda once read "Prions are not biology."
Through the 1980s and 1990s, Prusiner's group purified the protein, identified the PRNP gene, generated PrP-knockout mice that resisted prion infection, and transmitted disease to mice with synthetic PrP fibrils. He won the 1997 Nobel Prize in Physiology or Medicine. The decisive synthetic-prion experiment — producing infectious disease from purely chemically synthesized PrP — was published in 2010 by Surachai Supattapone's group.
The cultural impact was sharp. The British BSE crisis (peak 1992–93) and the emergence of variant CJD in 1996 forced a national reckoning with mad cow disease, blood-product safety, and meat industry practice. Over four million UK cattle were slaughtered. Blood donation from people who lived in the UK during the BSE years is still restricted in many countries decades later.
Treatment, prevention, and the future
No effective treatment exists. Pentosan polysulfate, doxycycline, quinacrine, flupirtine, and antibody trials have all failed to alter survival in clinical studies. Symptomatic management focuses on myoclonus (clonazepam), agitation, and supportive care.
The most promising current approaches:
- PRNP-lowering antisense oligonucleotides. Ionis Pharmaceuticals' ASO (ION717) reduces PrPC expression. In prion-infected mice, ASO treatment extended survival. A Phase 1/2 trial in symptomatic and pre-symptomatic patients is ongoing.
- Anti-PrP antibodies. Sonia Vallabh and Eric Minikel's lab and others are developing antibodies against PrPC to slow conversion.
- Small-molecule chaperones that stabilize PrPC in its native fold.
For families with PRNP mutations, predictive genetic testing carries weight. Many carriers choose not to know in the absence of treatment. Pre-implantation genetic diagnosis can prevent transmission within families.
Why prions matter beyond CJD
The deeper lesson of prion biology is that templated protein misfolding is a general engine of neurodegeneration. Amyloid-beta in Alzheimer's, tau in Alzheimer's and frontotemporal dementia, alpha-synuclein in Parkinson's and multiple system atrophy, TDP-43 in ALS, huntingtin in Huntington's, SOD1 in ALS — all show prion-like seeding and cell-to-cell propagation in animal models.
These are not classically infectious between people (there is no horizontal transmission of Alzheimer's). But cadaveric growth hormone has, in rare cases, transmitted both CJD prions and amyloid-beta seeds — proving that under the right exposure, even non-prion amyloids can propagate. Drug development across neurodegeneration now borrows directly from the prion playbook: lower the substrate, block the conversion, sequester the seeds.
Common misconceptions
- "Prions are a kind of virus." No. Viruses contain nucleic acid and protein. Prions are protein only.
- "You can catch prion disease from someone with sCJD by ordinary contact." No. Sporadic CJD is not transmissible by casual contact, sexual contact, droplets, or shared utensils. Transmission requires direct inoculation of CNS or surgical tissues.
- "Cooking destroys prions." No. Even sustained boiling and grilling are insufficient.
- "All cases of rapidly progressive dementia are CJD." No. Autoimmune encephalitis, viral encephalitis, paraneoplastic syndromes, and metabolic causes mimic CJD and are treatable — they must be excluded.
- "BSE is no longer a risk." Largely true in most countries with surveillance — but atypical BSE (L- and H-type) still appears sporadically, and chronic wasting disease in deer is spreading in North America with no confirmed human cases but ongoing concern.
| Type | Cause | Onset age | Course | Frequency | Distinct features |
|---|---|---|---|---|---|
| Sporadic CJD | Unknown (spontaneous) | ~60s | ~5 months | ~1/million/year | EEG periodic sharp waves; cortical ribbon on DWI |
| Familial CJD | PRNP mutation | 40s–60s | Variable | ~15% of all CJD | Family history; genetic testing |
| Iatrogenic CJD | Contaminated tissue/instruments | Variable | ~1–2 years | Rare | Cerebellar onset; history of exposure |
| Variant CJD | BSE beef ingestion | ~27 years | ~14 months | ~178 UK cases total | Pulvinar sign; psychiatric onset; florid plaques |
| Kuru | Ritual cannibalism | 5+ years | ~12 months | ~Extinct | Cerebellar ataxia dominant; Fore people of PNG |
| FFI | D178N + 129M | 40s–60s | ~1–2 years | ~Very rare | Intractable insomnia, dysautonomia, dementia |
| GSS | PRNP mutation (e.g., P102L) | 30s–60s | ~2–10 years | ~Very rare | Slowly progressive ataxia and dementia |
Frequently asked questions
What exactly is a prion?
A protein folded into a self-templating shape that converts other copies of the same protein into the same misfolded form. For the human disease the relevant protein is PrP, encoded by the PRNP gene on chromosome 20. The normal form PrP^C is rich in alpha-helix; the disease form PrP^Sc is rich in beta-sheet and is resistant to proteases. There is no DNA or RNA inside a prion — the protein alone is the infectious agent. Stanley Prusiner proposed the prion concept in 1982; he won the Nobel Prize in 1997. Other neurodegenerative diseases (Alzheimer's amyloid-beta, Parkinson's alpha-synuclein, ALS's TDP-43) show prion-like templated misfolding but are not classically infectious between people.
What human prion diseases exist and how common are they?
Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common — about 1 case per million people per year, no known trigger, peaks in the 60s. Variant CJD (vCJD) came from eating BSE-contaminated beef in the UK in the late 1980s and 1990s; ~178 confirmed UK cases. Familial CJD, Gerstmann-Sträussler-Scheinker, and fatal familial insomnia are inherited PRNP mutations. Iatrogenic CJD came from contaminated growth hormone, dura mater grafts, and neurosurgical instruments. Kuru — once epidemic among the Fore people of Papua New Guinea via ritual mortuary cannibalism — has effectively ended. Chronic wasting disease in deer is enzootic in North America.
How can a protein be infectious without a genome?
By templating. A single molecule of PrP^Sc binds a healthy PrP^C and forces it to refold into the same beta-sheet-rich shape. Now there are two infectious molecules. Each of those can convert two more. The amplification is autocatalytic. Misfolded molecules also stack into amyloid fibrils that can fragment, creating more templating seeds. No information storage in nucleic acid is required because the shape itself is the information.
Why are prions so hard to destroy?
The beta-sheet aggregate is extraordinarily stable. Prions survive standard autoclaving at 121°C for 15 minutes, 10% formaldehyde, 70% ethanol, and most surgical sterilization protocols that kill viruses and bacteria. Effective decontamination requires autoclaving at 134°C for 18 minutes plus 1N NaOH or 2N sodium hypochlorite. Reusable neurosurgical instruments used on CJD patients are typically incinerated. This resistance is why iatrogenic CJD has been a real risk in neurosurgery and ophthalmic surgery.
What does prion disease look like clinically?
Rapidly progressive dementia, myoclonus (sudden involuntary jerks), ataxia (loss of coordination), visual or behavioral disturbance, and akinetic mutism. EEG often shows periodic sharp wave complexes in sCJD. MRI shows cortical ribbon hyperintensity and basal ganglia changes on DWI. CSF 14-3-3 and RT-QuIC (which directly detects PrP^Sc seeding activity) are diagnostic biomarkers. Median survival from symptom onset is about 5 months for sCJD; 14 months for vCJD. Brain biopsy or post-mortem shows spongiform vacuolation, neuronal loss, and PrP plaques.
Is there a treatment or cure?
No effective treatment exists. Trials of pentosan polysulfate, doxycycline, quinacrine, and flupirtine have failed. The most promising current approaches are antisense oligonucleotides that lower PrP expression — PrP-lowering ASOs from Ionis are in clinical development after extending survival in prion-infected mice. Immunotherapy with anti-PrP antibodies is also being studied. For families with PRNP mutations, genetic counseling and pre-symptomatic counseling are essential because not all carriers want predictive testing for an untreatable disease.
Are Alzheimer's and Parkinson's prion diseases too?
Not classically — but they share the templated-misfolding engine. Amyloid-beta (Alzheimer's), tau, alpha-synuclein (Parkinson's, multiple system atrophy), TDP-43 (ALS, FTD), and SOD1 all show prion-like seeding and cell-to-cell spread in animal models. The term prionoid is sometimes used. Crucially, these proteins do not appear to be transmissible between humans under normal circumstances — but cadaveric pituitary growth hormone has transmitted both CJD prions and amyloid-beta seeds in rare cases. The prion paradigm now informs drug development across neurodegeneration broadly.